



Epigen Biosciences Licenses its LPA1 Receptor small molecule program to Novo Nordisk

Torreya advised Epigen on the license of its LPA1 receptor antagonist

San Diego, CA USA and Bagsværd, Denmark, May 23, 2018

Epigen Biosciences, a San Diego based biotechnology company focused on discovering therapies for unmet medical needs, announced it entered into a worldwide collaboration agreement to license its LPA1 receptor small molecule program including EPGN696 to Novo Nordisk for up to \$200 million.

EPGN696 is an orally available, selective LPA1 receptor antagonist for development in diabetic and chronic kidney disease, and other chronic diseases associated with metabolic syndrome. In preclinical testing EPGN696 demonstrated efficacy and safety in rodent models of kidney disease by targeting fibrosis, inflammation and growth factor responses.

Torreya served as financial advisor to Epigen on this transaction. This transaction reinforces Torreya's strength and leadership position as an advisor to biotechnology companies. Torreya has advised on 36 strategic and financing transactions in the life sciences industry in the last 18 months.

ABOUT EPIGEN BIOSCIENCES, INC

For more information about Epigen, please see: www.epigenbiosciences.com

ABOUT NOVO NORDISK A/S:

For more information about Novo Nordisk, please see: www.novonordisk.com

Deal Press Release

Torreya Contact

CHRISTINE FISCHETTE, PH.D.

Executive Director | New York Office

christine.fischette@torreyapartners.com | 973.978.0671 | torreya.com



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.